IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited’s subsidiary, Imaging Biometrics, has announced an FDA-approved Expanded Access Program in the United States for its oral gallium maltolate treatment, aimed at patients with specific types of brain tumors. This program provides early access to the potential treatment for eligible patients while the phase 1 clinical trial at the Medical College of Wisconsin is being concluded. The initiative highlights IQ-AI’s dedication to addressing urgent patient needs in the face of glioblastoma, with 40 patients initially allowed to enroll.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
